9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

 

Archive

Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma

Condition Malignant Mesothelioma|Metastatic Cancer Estimated Enrollment: 196 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: P00804|PAPWORTH-MESOVATS|PAPWORTH-P00804|EU-20901|ISRCTN34321019 Study First Received: January 13, 2009 Last Updated: June 27, 2013 Estimated Primary Completion Date: February 2013 Primary Outcome Measures: Survival at 1 year after treatment|Control of pleural effusion|Complications, including need for more surgery, persistent air leak requiring pleural intubation for > 10 days, and hospital stay for > 12 days|Symptoms and quality of life as assessed by the EuroQol questionnaire|Length of hospital stay|Exercise tolerance|Cost to the health service, in terms of resources used for...

Continue reading

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Condition Part A and B: Advanced Solid Malignancies|Part C: Malignant Mesothelioma Estimated Enrollment: 73 Age Group: 20 Years to 130 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Masking: No masking|Primary Purpose: Other Study ID Numbers: D4880C00010 Study First Received: May 14, 2014 Last Updated: April 12, 2017 Estimated Primary Completion Date: January 27, 2017 Primary Outcome Measures: Adverse event Sponsors and Collaborators: AstraZeneca Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02141347...

Continue reading

Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma

Condition Lung Cancer|Malignant Mesothelioma Estimated Enrollment: 20 Age Group: 20 Years to 70 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Primary Purpose: Treatment Study ID Numbers: CDR0000067177|RPCI-DS-96-25 Study First Received: November 1, 1999 Last Updated: March 3, 2011 Estimated Primary Completion Date: June 1998 Primary Outcome Measures: Sponsors and Collaborators: Roswell Park Cancer Institute Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00003974...

Continue reading

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

Condition Mesothelioma Estimated Enrollment: 8 Age Group: 19 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: F090917002 (UAB 0901)|UAB 0901 Study First Received: September 15, 2010 Last Updated: May 20, 2016 Estimated Primary Completion Date: April 2015 Primary Outcome Measures: Evaluation of the tumor response rate following zoledronic acid|Evaluation of the duration of tumor response Sponsors and Collaborators: University of Alabama at Birmingham|Novartis Pharmaceuticals Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01204203...

Continue reading

A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.

Condition Cancer Estimated Enrollment: 22 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: 2009/337 Study First Received: October 15, 2009 Last Updated: February 7, 2017 Estimated Primary Completion Date: September 2015 Primary Outcome Measures: Progression fee survival rate|Response rate according to modified RECIST criteria|Toxicity (CTCAE version 4)|Overall survival Sponsors and Collaborators: University Hospital, Ghent|Merck Sharp & Dohme Corp. Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00996567...

Continue reading

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Condition Advanced Malignant Mesothelioma|Localized Malignant Mesothelioma|Recurrent Malignant Mesothelioma Estimated Enrollment: 34 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: NCI-2009-00656|CDR0000539269|N0623|U10CA025224 Study First Received: April 11, 2007 Last Updated: January 28, 2015 Estimated Primary Completion Date: April 2009 Primary Outcome Measures: Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST)|Overall Survival|Progression-free Survival Assessed by RECIST|Determine the Clinical Toxicities of This Drug in This Participant Population.|Overall Best Response of Target Lesions to Pazopanib in Patients With MPM Based on the RECIST.|Overall Response...

Continue reading

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

Condition Malignant Pleural Mesothelioma|Solid Tumors Estimated Enrollment: 71 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CBP08-01 Study First Received: June 16, 2008 Last Updated: December 19, 2012 Estimated Primary Completion Date: July 2012 Primary Outcome Measures: Ph I: To determine the MTD of CBP501 + pemetrexed + cisplatin in patients with advanced solid tumors. Ph II: To evaluate the efficacy and safety profile of CBP501 + pemetrexed + cisplatin in patients with malignant pleural mesothelioma|Ph I: To determine the recommended CBP501 dose for exploration in the phase II part|Ph I:...

Continue reading

Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 30 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Primary Purpose: Treatment Study ID Numbers: CDR0000066141|P30CA016087|NYU-9850|MDA-FDR001234|MDA-ID-95209|NCI-G99-1575 Study First Received: December 10, 1999 Last Updated: March 25, 2011 Estimated Primary Completion Date: May 2001 Primary Outcome Measures: Sponsors and Collaborators: New York University School of Medicine|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00004033...

Continue reading

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

Condition Mesothelioma Estimated Enrollment: 77 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: ONC-2006-003|EUDRACT 2006-004429-27 Study First Received: December 4, 2006 Last Updated: August 31, 2011 Estimated Primary Completion Date: November 2010 Primary Outcome Measures: Time to progression (TTP) from first day of treatment until first observation of disease progression or death due to any cause or the last date the patient was known to be progression free or alive.|Response rate (RR) assessed according to modified RECIST criteria for Malignant Pleural Mesothelioma.|Overall survival (OS) computed as the time between the...

Continue reading

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Condition Advanced Malignant Mesothelioma|Recurrent Malignant Mesothelioma Estimated Enrollment: 39 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: NCI-2009-00693|CDR0000652058|NCIC-183 Study First Received: October 25, 2006 Last Updated: May 5, 2014 Estimated Primary Completion Date: January 2012 Primary Outcome Measures: Objective Response (Partial and Complete) Per RECIST Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: October 21, 2013 Website Link: https://ClinicalTrials.gov/show/NCT00392444...

Continue reading